Iranian Red Crescent Medical Journal

Published by: Kowsar

Construction of Recombinant Bacmid Containing M2e-Ctxb and Producing the Fusion Protein in Insect Cell Lines

Nima Mirzaei 1 , * , Talat Mokhtari Azad 2 , Rakhshandeh Nategh 2 , Hoorieh Soleimanjahi 3 and Nour Amirmozafari 4
Authors Information
1 Department of Biology, Science and Research branch, Islamic Azad University, Tehran, IR Iran
2 Department of Virology, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Virology, Tarbiat Modares University, Tehran, IR Iran
4 Department of Microbiology, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: February 7, 2014, 16 (2); e13176
  • Published Online: February 7, 2014
  • Article Type: Research Article
  • Received: June 30, 2013
  • Revised: July 27, 2013
  • Accepted: November 18, 2013
  • DOI: 10.5812/ircmj.13176

To Cite: Mirzaei N, Mokhtari Azad T, Nategh R, Soleimanjahi H, Amirmozafari N. Construction of Recombinant Bacmid Containing M2e-Ctxb and Producing the Fusion Protein in Insect Cell Lines, Iran Red Crescent Med J. 2014 ; 16(2):e13176. doi: 10.5812/ircmj.13176.

Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. WHO Position Paper on Influenz a Vaccines: Selected references. 2005;
  • 2. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006; 295(8): 891-4[DOI][PubMed]
  • 3. Hehme N, Colegate T, Palache B, Hessel L. Influenza vaccine supply: building long-term sustainability. Vaccine. 2008; 26 Suppl 4-6[PubMed]
  • 4. Global pandemic influenza action plan to increase vaccine supply, Vaccines and Biologicals Epidemic and Pandemic Alert and Response. 2006;
  • 5. Cunha BA. Influenza: historical aspects of epidemics and pandemics. Infect Dis Clin North Am. 2004; 18(1): 141-55[DOI][PubMed]
  • 6. Kuiken T, Fouchier R, Rimmelzwaan G, Osterhaus A. Emerging viral infections in a rapidly changing world. Curr Opin Biotechnol. 2003; 14(6): 641-6[PubMed]
  • 7. Nicholson KG, Webster RG, Hay AJ. Genetic Reassortment of Human Influenza Viruses in Nature, Textbook of Influenza. 1998;
  • 8. International Federation of Pharmaceutical Manufacturers & Associations. Influenza vaccine supply international task force. Technical briefing for WHO intergovernmental meeting on sharing of influenza viruses and access to vaccines and other benefits. 2007;
  • 9. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005; 18(1): 244-51[DOI][PubMed]
  • 10. Palache B. New vaccine approaches for seasonal and pandemic influenza. Vaccine. 2008; 26(49): 6232-6[DOI][PubMed]
  • 11. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine. 2008; 26(27-28): 3395-403[DOI][PubMed]
  • 12. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol. 1994; 68(3): 1551-63[PubMed]
  • 13. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine. 2008; 26(2): 201-14[DOI][PubMed]
  • 14. Pinto LH, Lamb RA. The M2 proton channels of influenza A and B viruses. J Biol Chem. 2006; 281(14): 8997-9000
  • 15. Razavi NH, Soleimanjahi H, Fotouhi F, Ghaemi A, Fazeli M. Construction of the Chimeric HSP70-E7 Vector and Evaluation of its Protein Production. Iran J Virol. 2009; 3(3): 29-34
  • 16. Areas AP, Oliveira ML, Miyaji EN, Leite LC, Aires KA, Dias WO, et al. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun. 2004; 321(1): 192-6[DOI][PubMed]
  • 17. Müller D, Bayer K, Mattanovich D. Potentials and limitations of prokaryotic and eukaryotic expression systems for recombinant protein production--a comparative view. Microb Cell Fact. 2006; 5: 61
  • 18. van Oers MM. Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv Virus Res. 2006; 68: 193-253[DOI][PubMed]
  • 19. Yamshchikov GV, Ritter GD, Vey M, Compans RW. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology. 1995; 214(1): 50-8[DOI][PubMed]
  • 20. Airenne KJ, Peltomaa E, Hytonen VP, Laitinen OH, Yla-Herttuala S. Improved generation of recombinant baculovirus genomes in Escherichia coli. Nucleic Acids Res. 2003; 31(17)[PubMed]
  • 21. Gouya MM, Nabavi M, Soroush M, Haghdoust AA, Ghalehee S, Hemmati P, et al. Mortality from Pandemic Influenza A (H1N1) in Iran. Iran Red Crescent Med J. 2011; 13(10): 698-701[PubMed]
  • 22. Lankarani KB, Sabayan B. H1N1 influenza pandemics 2009: from myths to facts. Iran Red Cres Med J. 2010; 12(4): 354-7
  • 23. Ebrahimi SM, Aghaiypour K, Nili H. Sequence analysis of M2 gene of avian influenza virus strain (A/Chicken/Iran/101/98 (H9N2)) as an oil vaccine seed. Iran J Biotech. 2008; 6(4)
  • 24. Ebrahimi SM, Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes. 2011; 42(1): 1-8[DOI][PubMed]
  • 25. Andersson AM, Hakansson KO, Jensen BA, Christensen D, Andersen P, Thomsen AR, et al. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS One. 2012; 7(10)[DOI][PubMed]
  • 26. Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, et al. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS One. 2012; 7(9)[DOI][PubMed]
  • 27. Harakuni T, Sugawa H, Komesu A, Tadano M, Arakawa T. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems. Infect Immun. 2005; 73(9): 5654-65[DOI][PubMed]
  • 28. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines. 2009; 8(4): 499-508[DOI][PubMed]
  • 29. Ebrahimi SM, Tebianian M, Mirjalili A, Paykari H, Varshovi HR, Toghyani H, et al. Fusion and sequence analysis of the influenza A (H9N2) virus M2e and C-terminal fragment of Mycobacterium tuberculosis HSP70 (H37Rv). Arch Razi. 2009; 64(2): 71-6
  • 30. Kim EH, Lee JH, Pascua PN, Song MS, Baek YH, Kwon HI, et al. Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice. Virol J. 2013; 10: 104[DOI][PubMed]
  • 31. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol. 2002; 83: 1851-9[PubMed]
  • 32. Smith GE, Summers MD, Fraser MJ. Production of human beta interferon in insect cells infected with a baculovirus expression vector. Mol Cell Biol. 1983; 3(12): 2156-65[PubMed]
  • 33. Belzhelarskaia SN. [A baculovirus expression system for insect cells]. Mol Biol (Mosk). 2002; 36(3): 371-85[PubMed]
  • 34. Kidd IM, Emery VC. The use of baculoviruses as expression vectors. Applied Biochem Biotech. 1993; 42(2-3): 137-59
  • 35. Li SF, Wang HL, Hu ZH, Deng F. Genetic modification of baculovirus expression vectors. Virol Sin. 2012; 27(2): 71-82[DOI][PubMed]
  • 36. Margine I, Martinez-Gil L, Chou YY, Krammer F. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One. 2012; 7(12)[DOI][PubMed]
  • 37. Rezaei F, Mirshafiey A, Shahmahmoodi S, Shoja Z, Ghavami N, Mokhtari-Azad T. Influenza Virus-like Particle Containing Two Different Subtypes of Hemagglutinin Confers Protection in Mice Against Lethal Challenge With A/PR8 (H1N1) and A/HK (H3N2) Viruses. Iran Red Crescent Med J. 2013; 15(1): 75-82[DOI][PubMed]
  • 38. Safdar A, Cox MM. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin Investig Drugs. 2007; 16(7): 927-34[DOI][PubMed]
  • 39. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine. 1995; 13(15): 1399-402[PubMed]
  • 40. Salmani Z, Behzadian F, Fotouhi Chahooki F, Fallah J. Construction of a Recombinant Bacmid DNA to Express Influenza Virus Matrix Protein1 (M1) in Insect Cell Line. Iran J Virol. 2010; 4(3): 23-8
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments